Enliven Therapeutics Ratios and Metrics

Market cap in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	Current	2023	2022	2021	2020
Market Capitalization	804	570	108	59	384
Market Cap Growth	-	430.51%	81.86%	-84.60%	-
Enterprise Value	551	317	32	-31	296
PE Ratio	-7.97	-7.97	-2.85	-1.15	-7.80
PB Ratio	3.27	2.32	-1.40	0.69	4.55
P/FCF Ratio	-9.29	-9.29	-3.29	-1.26	-10.26
P/OCF Ratio	-9.31	-9.31	-3.35	-1.26	-10.26
EV/EBITDA Ratio	-4.47	-4.47	-0.85	0.59	-7.16
EV/EBIT Ratio	-4.43	-4.43	-0.85	0.59	-7.15
EV/FCF Ratio	-5.16	-5.16	-0.98	0.65	-7.90
Debt / Equity Ratio	-	-	-	0.01	-
Debt / EBITDA Ratio	-	-	-	-0.01	-
Debt / FCF Ratio	-	-	-	-0.01	-
Quick Ratio	9.78	9.78	7.78	12.52	14.12
Current Ratio	10.28	10.28	8.00	12.86	14.47
Return on Equity (ROE)	-26.60%	-26.60%	430.40%	-63.10%	-50.40%
Return on Assets (ROA)	-25.20%	-25.20%	-51.90%	-57.90%	-47.70%
Return on Capital (ROIC)	-33.97%	-33.97%	50.49%	-59.35%	-49.38%
Earnings Yield	-8.90%	-12.55%	-35.03%	-86.91%	-12.82%
FCF Yield	-7.64%	-10.77%	-30.40%	-79.13%	-9.75%
Buyback Yield / Dilution	-1037.74%	-1037.74%	42.31%	-55.56%	-1882.29%
Total Shareholder Return	-1037.74%	-1037.74%	42.31%	-55.56%	-1882.29%

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).